🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Recruitingn/aAges 18 Years - anyAllBeijing Chao Yang Hospital
NCT06950697 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint inhibitors (ICIs) therapy. The primary questions it aims to address are: 1. What is the real-world incidence of VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 2. What are the risk factors and biomarkers for VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 3. What is the impact of VTE/ATE on the prognosis of lung cancer patients receiving immune checkpoint inhibitors? Researchers will compare the characteristics and biomarkers of patients with and without ICI-associated VTE/ATE to identify novel specific biomarkers for thrombotic events. Furthermore, they will construct a risk assessment model for thrombotic events t

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥18 years * Histopathologically confirmed lung cancer diagnosis at enrollment * Received at least one dose of a China-approved lung cancer immune checkpoint inhibitor * Signed informed consent form Exclusion Criteria: * Presence of two or more primary cancers * Missing data for key variables * Inability to comply with follow-up requirements * Presence of VTE/ATE at the time of ICI initiation
💊

What it tests

  • Not listed
📍

Where

5 sites
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
The Fourth Hospital of Inner Mongolia Autonomous Region
Hohhot, China
Beijing Chaoyang Hospital, Capital Medical University
Beijing, China
Beijing Luhe Hospital, Capital Medical University
Beijing, China
China-japan Friendship Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy